Skip to main
ACIU
ACIU logo

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA is a clinical-stage biopharmaceutical company specializing in neurodegenerative diseases, with a focus on developing therapeutic and diagnostic products targeting misfolded proteins. The company's promising pipeline includes ACI-7104.056, which has shown a significant 20-fold increase in antibodies against pathogenic variants of aSyn, paving the way for further efficacy assessments. Additionally, the anticipated positive results from the upcoming EVOKE trial for Alzheimer’s disease patients may enhance interest in their NLRP3 program, aligning with the industry's current shift towards safer and more effective treatment strategies.

Bears say

AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, highlighting ongoing financial challenges. The company is exposed to significant risks typical of the biopharmaceutical industry, including potential negative outcomes from clinical trials, regulatory uncertainties, and the pressures of navigating complex and price-sensitive commercial markets. These factors contribute to a negative outlook regarding the company's financial stability and future prospects.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.